PET scan test for glioblastoma and kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new PET scan tracer called [68Ga]Ga-XT771 to see if it can better detect glioblastoma (a type of brain tumor) and clear cell renal cell carcinoma (a type of kidney cancer). If you have one of these cancers, this scan might help your doctor see the tumor more clearly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have been diagnosed with glioblastoma or clear cell renal cell carcinoma.
- You must be able to sign a consent form agreeing to join the study.
- You should not have a known allergy to any part of the study drug or similar drugs.
- You should not have any other condition that the doctor thinks might make the study drug unsafe for you.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new PET/CT scan that uses a special tracer to find clear cell kidney cancer. If you are scheduled for kidney tumor removal, this scan may help your surgeon see the cancer more clearly before surgery.
This study uses a special PET/CT scan (called 68Ga-NYM096) to see if it can help find different types of cancer. The scan may help doctors get clearer pictures of where cancer is in your body.
This trial tests a new PET imaging agent that may help detect and evaluate kidney masses suspected to be kidney cancer, including early or recurring cases. It could help doctors better understand the tumor before deciding on treatment.
This trial uses a special imaging scan (68Ga-C1 PET/CT) to see kidney cancer more clearly. It helps doctors find and understand clear cell renal cell carcinoma, a common type of kidney cancer.
This trial tests a new type of PET scan to better see kidney tumors. It may help doctors understand the tumor better before biopsy or surgery.
This early-stage trial tests a new type of imaging scan (called PET) that uses a special tracer to help doctors see tumors better. The scan targets a protein called CAIX that appears on many cancer cells, which may help with accurate diagnosis and staging.
Hear when a new Clear Cell Renal Cell Carcinoma and Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.